

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 30, 2025

PARP Antibody

RRID:AB_2160739

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 9542, RRID:AB_2160739)

Antibody Information

URL: http://antibodyregistry.org/AB_2160739

Proper Citation: (Cell Signaling Technology Cat# 9542, RRID:AB_2160739)

Target Antigen: PARP

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W. Consolidation: AB_10694650, AB_2160726, AB_10831365.

Antibody Name: PARP Antibody

Description: This polyclonal targets PARP

Target Organism: rat, h, m, mouse, r, non-human primate, human, mk

Antibody ID: AB_2160739

Vendor: Cell Signaling Technology

Catalog Number: 9542

Alternative Catalog Numbers: 9542S, 9542P, 9542L

Record Creation Time: 20231110T075857+0000

Record Last Update: 20241115T094614+0000

Ratings and Alerts

No rating or validation information has been found for PARP Antibody.

No alerts have been found for PARP Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 243 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Dunlap KN, et al. (2025) SLC7A5 is required for cancer cell growth under arginine-limited conditions. *Cell reports*, 44(1), 115130.

Zhang Q, et al. (2024) Co-inhibition of BET and NAE enhances BIM-dependent apoptosis with augmented cancer therapeutic efficacy. *Biochemical pharmacology*, 223, 116198.

Liu Z, et al. (2024) FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition. *Cell reports*, 43(7), 114464.

Tsamouri LP, et al. (2024) The hydrophobicity of the CARD8 N-terminus tunes inflammasome activation. *Cell chemical biology*, 31(9), 1699.

Isermann T, et al. (2024) Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition. *bioRxiv : the preprint server for biology*.

Andronikou C, et al. (2024) PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair. *The EMBO journal*, 43(6), 1015.

Leszczynska KB, et al. (2024) H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells. *Cell reports*, 43(2), 113707.

Liu K, et al. (2024) A beneficial adaptive role for CHOP in driving cell fate selection during ER stress. *EMBO reports*, 25(1), 228.

Wu D, et al. (2024) The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma. *BMC cancer*, 24(1), 928.

Geraud M, et al. (2024) TDP1 mutation causing SCAN1 neurodegenerative syndrome hampers the repair of transcriptional DNA double-strand breaks. *Cell reports*, 43(5), 114214.

Nguele Meke F, et al. (2024) Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models. *Cancer research*

communications, 4(1), 5.

Hwang GH, et al. (2024) A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma. *Cancer research*, 84(6), 872.

Caggiano C, et al. (2024) Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. *Cell reports*, 43(9), 114751.

White MC, et al. (2024) Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. *Cancer research communications*, 4(4), 1024.

Becker JH, et al. (2024) Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. *Cancer research*, 84(21), 3629.

Lizardo MM, et al. (2024) Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4464.

Martini APR, et al. (2024) Acrobatic training prevents learning impairments and astrocyte remodeling in the hippocampus of rats undergoing chronic cerebral hypoperfusion: sex-specific benefits. *Frontiers in rehabilitation sciences*, 5, 1375561.

Sinha NK, et al. (2024) The ribotoxic stress response drives UV-mediated cell death. *Cell*, 187(14), 3652.

Xi J, et al. (2024) Initiation of a ZAK γ -dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L. *Cell reports*, 43(4), 113998.

Fedry J, et al. (2024) Visualization of translation reorganization upon persistent ribosome collision stress in mammalian cells. *Molecular cell*, 84(6), 1078.